Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention1: Standard of care plus Haldi 30 drops: Standard of care plus 3 drops PO at 6 AM, 10 AM, 2 PM, 6 PM, 10 PM.
No liquid or solid food or oral medication up to 20 minutes after drug administ
Sponsors
Dr Sarang Phadke
Col Suresh Purushottam Gadgil
Mr Anant Krishnaji Joshi
Mr Narahar Krishna Phadke
Mr Nikhil Vishwas Ranade
Mr Sunil Danekar
Mr Vishwas Digambar Ranade
Sanmarga Pratishthan
Eligibility
Inclusion criteria
Inclusion criteria: COVID 19 positive patients 1 Mild category Group A Asymptomatic but positive for COVID 19. Group B Symptomatic URTI without comorbidity. Group C Symptomatic URTI with comorbidity. 2 Moderate category Pneumonia hypoxia , fever , cough including SpO2 less than 94 percent Range 90 to 94 percent on room air. Respiratory Rate more or equal to 24 per minute. 3. Male or non-pregnant female of Age >= 18 years at time of consent. 4. Women of child bearing potential agree to abstinence or one primary form of non-hormonal contraception during the study period. 5. Subject / LAR willing to give informed consent for the study and agrees not to participate in another clinical trial for COVID-19 during the course of this study and further agrees to be randomized to any treatment arm of the study.
Exclusion criteria
Exclusion criteria: COVID 19 positive patients 1 Stage II B Group E Pneumonia LRTI with respiratory failure. 2 Stage III Group F Pneumonia LRTI with respiratory failure multi organ dysfunction syndrome. 3 Physician makes the decision that trial is not in the best interest of the patient. 4 Anticipated discharge to another hospital within 72 hours. 5 Subject already on another trial for COVID-19
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to RecoveryTimepoint: Time to Recovery as defined on the Ordinal Scale censured at day 7 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1 Change from baseline in monitored laboratory values 2 Change from baseline in Ordinal scale assessment 3 Mortality at day 7 4 Duration of hospitalization, use of NIV/HFNO 5 Incidence of new use of IMV/ECMOTimepoint: Day 3, Day 5 ,Day 7 | — |
Countries
India
Contacts
Public ContactDr Sarang Phadke
Sahyadri Hospitals Limited
Outcome results
None listed